These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 25246230)

  • 21. Delivery of recombinant proteins via the cerebrospinal fluid as a therapy option for neurodegenerative lysosomal storage diseases.
    Hemsley KM; Hopwood JJ
    Int J Clin Pharmacol Ther; 2009; 47 Suppl 1():S118-23. PubMed ID: 20040322
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intracerebroventricular dosing of N-sulfoglucosamine sulfohydrolase in mucopolysaccharidosis IIIA mice reduces markers of brain lysosomal dysfunction.
    Magat J; Jones S; Baridon B; Agrawal V; Wong H; Giaramita A; Mangini L; Handyside B; Vitelli C; Parker M; Yeung N; Zhou Y; Pungor E; Slabodkin I; Gorostiza O; Aguilera A; Lo MJ; Alcozie S; Christianson TM; Tiger PMN; Vincelette J; Fong S; Gil G; Hague C; Lawrence R; Wendt DJ; Lebowitz JH; Bunting S; Bullens S; Crawford BE; Roy SM; Woloszynek JC
    J Biol Chem; 2022 Dec; 298(12):102625. PubMed ID: 36306823
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Robust LC-MS/MS methods for analysis of heparan sulfate levels in CSF and brain for application in studies of MPS IIIA.
    Makower Å; Arnelöf E; Andersson T; Edlund PO; Gustavsson S; Janson J; Gelius SS; Tjernberg A
    Bioanalysis; 2019 Aug; 11(15):1389-1403. PubMed ID: 31490106
    [No Abstract]   [Full Text] [Related]  

  • 24. Disease stage determines the efficacy of treatment of a paediatric neurodegenerative disease.
    Hassiotis S; Beard H; Luck A; Trim PJ; King B; Snel MF; Hopwood JJ; Hemsley KM
    Eur J Neurosci; 2014 Jun; 39(12):2139-50. PubMed ID: 25068161
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enzyme-replacement therapy from birth delays the development of behavior and learning problems in mucopolysaccharidosis type IIIA mice.
    Gliddon BL; Hopwood JJ
    Pediatr Res; 2004 Jul; 56(1):65-72. PubMed ID: 15128919
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravenous delivery of a chemically modified sulfamidase efficiently reduces heparan sulfate storage and brain pathology in mucopolysaccharidosis IIIA mice.
    Gustavsson S; Ohlin Sjöström E; Tjernberg A; Janson J; Westermark U; Andersson T; Makower Å; Arnelöf E; Andersson G; Svartengren J; Ekholm C; Svensson Gelius S
    Mol Genet Metab Rep; 2019 Dec; 21():100510. PubMed ID: 31528541
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Temporospatial Development of Neuropathologic Findings in a Canine Model of Mucopolysaccharidosis IIIB.
    Harm TA; Hostetter SJ; Nenninger AS; Valentine BN; Ellinwood NM; Smith JD
    Vet Pathol; 2021 Jan; 58(1):205-222. PubMed ID: 33205707
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intrathecal enzyme replacement therapy: successful treatment of brain disease via the cerebrospinal fluid.
    Dickson P; McEntee M; Vogler C; Le S; Levy B; Peinovich M; Hanson S; Passage M; Kakkis E
    Mol Genet Metab; 2007 May; 91(1):61-8. PubMed ID: 17321776
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of a C57BL/6 congenic mouse strain of mucopolysaccharidosis type IIIA.
    Crawley AC; Gliddon BL; Auclair D; Brodie SL; Hirte C; King BM; Fuller M; Hemsley KM; Hopwood JJ
    Brain Res; 2006 Aug; 1104(1):1-17. PubMed ID: 16828069
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chemically modified recombinant human sulfamidase (SOBI003) in mucopolysaccharidosis IIIA patients: Results from an open, non-controlled, multicenter study.
    Harmatz P; Muenzer J; Ezgü F; Dalén P; Huledal G; Lindqvist D; Gelius SS; Wikén M; Önnestam K; Bröijersén A
    Mol Genet Metab; 2022 Aug; 136(4):249-259. PubMed ID: 35835061
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of chemical modification of sulfamidase on distribution to brain interstitial fluid and to CSF after an intravenous administration in awake, freely-moving rats.
    Janson J; Andersson G; Bergquist L; Eriksson M; Folgering JHA
    Mol Genet Metab Rep; 2020 Mar; 22():100554. PubMed ID: 31908953
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sulfamidase deficiency in a family of Dachshunds: a canine model of mucopolysaccharidosis IIIA (Sanfilippo A).
    Fischer A; Carmichael KP; Munnell JF; Jhabvala P; Thompson JN; Matalon R; Jezyk PF; Wang P; Giger U
    Pediatr Res; 1998 Jul; 44(1):74-82. PubMed ID: 9667374
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term neurological effects of bone marrow transplantation in a canine lysosomal storage disease.
    Shull RM; Breider MA; Constantopoulos GC
    Pediatr Res; 1988 Sep; 24(3):347-52. PubMed ID: 3145485
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of canine fucosidosis by intracisternal enzyme infusion.
    Kondagari GS; King BM; Thomson PC; Williamson P; Clements PR; Fuller M; Hemsley KM; Hopwood JJ; Taylor RM
    Exp Neurol; 2011 Aug; 230(2):218-26. PubMed ID: 21575633
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Helper-dependent canine adenovirus vector-mediated transgene expression in a neurodegenerative lysosomal storage disorder.
    Lau AA; Rozaklis T; Ibanes S; Luck AJ; Beard H; Hassiotis S; Mazouni K; Hopwood JJ; Kremer EJ; Hemsley KM
    Gene; 2012 Jan; 491(1):53-7. PubMed ID: 21963444
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Purification and characterization of recombinant murine sulfamidase.
    Gliddon BL; Yogalingam G; Hopwood JJ
    Mol Genet Metab; 2004 Nov; 83(3):239-45. PubMed ID: 15542395
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Whole Body and CNS Biodistribution of rhHNS in Cynomolgus Monkeys after Intrathecal Lumbar Administration: Treatment Implications for Patients with MPS IIIA.
    Chung JK; Pan L; Palmieri K; Youssef AS; McCauley TG
    Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29194406
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Delivery of recombinant gene product to canine brain with the use of microencapsulation.
    Barsoum SC; Milgram W; Mackay W; Coblentz C; Delaney KH; Kwiecien JM; Kruth SA; Chang PL
    J Lab Clin Med; 2003 Dec; 142(6):399-413. PubMed ID: 14713892
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase 1/2 study of intrathecal heparan-N-sulfatase in patients with mucopolysaccharidosis IIIA.
    Jones SA; Breen C; Heap F; Rust S; de Ruijter J; Tump E; Marchal JP; Pan L; Qiu Y; Chung JK; Nair N; Haslett PAJ; Barbier AJ; Wijburg FA
    Mol Genet Metab; 2016 Jul; 118(3):198-205. PubMed ID: 27211612
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of a mutation causing mucopolysaccharidosis type IIIA in New Zealand Huntaway dogs.
    Yogalingam G; Pollard T; Gliddon B; Jolly RD; Hopwood JJ
    Genomics; 2002 Feb; 79(2):150-3. PubMed ID: 11829484
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.